Douglas Swirsky

Insider Reports History

Entity
Individual
Location
C/O Rexahn Pharmaceuticals, Inc., 15245 Shady Grove Road Suite 455, Rockville, MD
Signature
/s/ Christina Blakley, attorney-in-fact for Douglas Swirsky
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Douglas Swirsky:

Stock Role Class Num Shares Value Price $ Report Date Ownership
MAXCYTE, INC. CHIEF FINANCIAL OFFICER Common Stock 81.3K $374K $4.60 Mar 15, 2024 Direct
MAXCYTE, INC. CHIEF FINANCIAL OFFICER Employee Stock Option (right to buy) 225K Mar 15, 2024 Direct
Cellectar Biosciences, Inc. Director Stock option (right to buy) 90K Jun 14, 2024 Direct

Insider Reports Filed by Douglas Swirsky

Symbol Company Period Transactions Value $ Form Type Date Filed Role
CLRB Cellectar Biosciences, Inc. Jun 14, 2024 1 $0 4 Jun 18, 2024 Director
MXCT MAXCYTE, INC. Mar 15, 2024 2 $0 4 Mar 19, 2024 CHIEF FINANCIAL OFFICER
CLRB Cellectar Biosciences, Inc. Jun 28, 2023 1 $0 4 Jun 28, 2023 Director
MXCT MAXCYTE, INC. Mar 27, 2023 1 $0 4 Mar 28, 2023 Chief Financial Officer
MXCT MAXCYTE, INC. Mar 27, 2023 0 $0 3 Mar 28, 2023 Chief Financial Officer
CLRB Cellectar Biosciences, Inc. Jun 24, 2022 1 $0 4 Aug 1, 2022 Director
CLRB Cellectar Biosciences, Inc. Sep 14, 2021 1 $26K 4 Sep 14, 2021 Director
CLRB Cellectar Biosciences, Inc. Jun 30, 2021 1 $0 4 Jul 2, 2021 Director